Alivus Life (ALIVUS)

FairStock Score: 48/100 — MIXED

Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I wear Buffett's glasses and Graham's shield: I ask whether this pharma business earns high returns on capital without debt, and whether the price leaves me a margin of safety. Alivus Life shows ROE 21.42% and ROCE 24.92%, with debt/equity just 0.02—prima facie a high-quality, conservatively financed operation. The latest quarter had sales of ₹673 Cr and net profit of ₹150 Cr, implying strong profitability, and a Piotroski F-Score of 7/9 supports financial strength. Profit growth of 31.71% is eye-catching, but sales growth of 8.51% and five-year revenue CAGR of 6.25% tell me this is not a hyper-growth machine; it is a stalwart unless margins or sales accelerate. Promoter holding of 74.91% aligns interests, though it also means lower float. Valuation is the rub: at ₹1,386.70, market cap ₹17,025 Cr, P/E 28.25, P/B 5.12, and book value ₹271.02, I am paying well above book for those returns. PEG 1.41 is not outrageous but not cheap. Dividend yield 0.36% offers little income cushion. Graham would remind me that P/B 5.12 and P/E 28.25 already capitalise the recent profit jump; if profit growth normalises, multiple compression can hurt. The low dividend yield also means total return depends heavily on earnings compounding or re-rating, not cash returned to owners. The 52-week range ₹819–₹1,493.80 shows the stock is near its high, and FairStock Score 48/100 says mixed. I would admire the debt-free-like balance sheet and capital efficiency, but I would demand a wider discount before buying. Great business traits do not automatically make a great purchase at this price.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer